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ABSTRACT 
 
 
 
Streptococcus agalactiae (GBS) is a common bacterium found commensally in the vaginal 
mucosa of healthy adults. GBS also causes severe infection in neonates, often leading to meningitis, 
which can cause lifelong health consequences including impaired hearing and seizures. Infection 
of newborns mainly arises from a colonized mother, either before birth through ascending infection 
or during labor. Ascending infection, where the bacteria travel to the fetus from the vaginal mucosa, 
is especially concerning as it can lead to loss of pregnancy or premature birth. The most common 
method of neonatal GBS disease prevention is antibiotic prophylaxis during delivery, though this 
method is lacking in safety and application. A promising alternative target for GBS virulence 
attenuation involves capsular polysaccharide (CPS), which protects GBS from immune recognition 
and clearance. CPS is regulated by CpsA, a multifunctional protein which is implicated in 
transcriptional activation, and ligation of CPS to the cell wall via the LytR domain. In this study, a 
CpsA mutant was created with two amino acid substitutions in the LytR domain which were 
predicted to decrease LytR functionality. We used microscopy to determine that this mutant 
induced a change in chain length, as well FL-vancomycin to show that this phenotypic change was 
not due to a change in cell envelope structure. We measured CPS levels with an ELISA to show 
that this mutant causes a reduction in CPS level. Finally, we analyzed virulence in zebrafish of 
bacteria expressing the mutant and found that virulence was increased in WT GBS with this mutant. 
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INTRODUCTION 
 
 
 
Streptococcus agalactiae (GBS) is a bacterium found commensally in the vaginal 
mucosa of healthy adults (1). While commensal in adults, GBS also causes severe systemic 
infection in neonates. Neonatal diseases caused by GBS can be either early onset 
(appearing less than 7 days after birth) or late onset (appearing past the first 7 days) (5). 
Both presentations of the disease can have major short-term and long-term dangers, often 
leading to sepsis and meningitis, which can cause lifelong health consequences including 
impaired hearing and seizures (2). Infection of newborns can arise from a colonized mother 
via ascending infection through the chorioamniotic membrane, or from birth in which the 
neonate comes in direct contact with the colonized vaginal tract (3). Infection can 
additionally come from other colonized women who may have contact with the neonate 
after birth. Ascending infection, in which the bacteria move through the choriodecidual 
membrane to infect the fetus, is especially concerning as it can lead to loss of pregnancy 
or premature birth (17).   
Pregnant women are tested for GBS colonization at around 35 weeks of pregnancy, 
and intrapartum prophylactic antibiotics are given to the mother during birth to prevent 
early onset disease, but this does not prevent late onset disease (5). Additionally, while the 
prevalence of GBS neonatal disease has declined since the rise in antibiotic prophylactics, 
the World Health Organization (WHO) estimated the global prevalence in 2017 to be 
410,000 neonatal infections with 150,000 deaths (20). A likely major contributor to this 
high prevalence is that at-home births are more common in low-income due to lack of 
access to hospital care, and thus a hospital-administered antibiotic treatment is not a viable 
	 	 	
	
	 2 
option. Additionally, antibiotic use on pregnant women or on any infected neonate can 
have lasting effects on the child’s immune development as well as the mother’s own 
microbiome (21). Further emphasizing this concern is the possibility of selecting for GBS 
populations which are resistant to antibiotics, which could lead to further health 
considerations (4). Following these downfalls of current treatment methods, alternative 
methods of preventative GBS therapeutics would be very valuable for prevention of this 
infection.   
Possible targets for GBS attenuation might include targeting of cell envelope 
components such as bacterial capsule. Capsular polysaccharide (CPS) is necessary in GBS 
for protection against phagocytosis and other immune responses (5, 6). In zebrafish models 
of GBS systemic infection, capsule production directly correlates to successful systemic 
infection (7). In particular, systemic infection is drastically impacted by deletion of the 
cpsA gene, the first gene in the capsule operon. In one study, wild type GBS (WT) had 
almost 100% mortality in adult zebrafish after 7 days. Comparatively, a deletion strain 
lacking cpsA gene (∆cpsA) had below 40% mortality even after 7 days within the same 
study (7). Deletion of cpsA in GBS leads to a significant reduction in capsule production, 
possibly explaining the observed drop in zebrafish mortality (7).    
CpsA is a 484 amino acid multifunctional protein common to all serotypes of GBS 
(8, 9). CpsA belongs to protein family LCP (LytR-CpsA-Psr), which is a protein family 
associated with creation and maintenance of the cell envelope (10). CpsA has four 
functional regions, namely an intracellular DNA-binding region with 3 transmembrane 
domains, an extracellular accessory domain, and an extracellular LytR domain. The DNA 
binding region was shown to bind specifically to the capsule operon promoter to 
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upregulate, or activate, operon transcription (7). Episomal, or extra-chromosomal plasmid-
based, expression of this intracellular region alone causes a significant increase in ∆cpsA 
capsule levels. Episomal expression of full CpsA protein has the same effect, and neither 
significantly influence the WT strain.    
While this intracellular region has a more conclusive function, the extracellular 
domains are less well understood. Crystal structure of homologous S. pneumoniae Cps2A 
shows separate folding of the accessory domain and LytR domain, and a pyro-
phosphorylated polyprenol phosphate lipid was found within the LytR domain of the 
crystal structure (10). This could indicate that the LytR domain is responsible for CPS 
attachment, as CPS attachment to the peptidoglycan is thought to involve a carrier lipid 
(10). Despite these predictions, narrowing down the exact functional mechanism of this 
region has been challenging. Episomal expression of CpsA truncated immediately before 
the LytR domain doesn’t complement for capsule production in ∆cpsA, and additionally 
causes a major decrease in capsule production in the WT strain (7). Following these 
findings, this dominant-negative effect was also observed with expression of a region 
between the accessory domain and the LytR domain (11), implicating this linker region in 
capsule production as well.    
In addition to these associations with capsule production and cell wall maintenance, 
CpsA also appears to have a role in the length of streptococcal chains. Streptococcal chain 
length is has been reported to correlate to better host immune evasion in other streptococci, 
possibly due to better evasion of complement recognition in the blood (22). Because of 
this, variations in chain length could contribute variations in virulence. ∆cpsA strains are 
known to have large variability in chain length ranging from 2 cells per chain to far over 
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10 cells per chain, compared to WT’s normal 2-5 cells per chain (11). In addition to 
decreasing capsule levels in WT strains, episomal expression of LytR-truncated CpsA 
causes an increase in chain length in WT strains which is normally only observed in the 
full knockout strain ∆cpsA. It is unclear how this morphology connects to the role of CpsA 
in capsule production, or how the loss of the LytR domain contributes to it.  One proposed 
explanation involves LytR as a regulator of cell wall degradation during cell division (7). 
This role would be consistent with the results of the truncation tests, where LytR-truncation 
leads to decreased separation of newly divided cells. 
Additionally, in Cps2A crystal structure was found a lipid co-isolate, indicating 
some role in lipid binding (10). The lipid was bound to a group of negatively charged, 
hydrophobic amino acids within Cps2A which are conserved in all LCP proteins. Several 
of these amino acids bind the phosphate head group of the lipid, such as R374 (R378 in 
GBS CpsA), whilst others are thought to aid bond stabilization, such as Q378 (Q382 in 
GBS CpsA) (10).  
Based on these previous studies, the LytR domain is predicted to have some 
enzymatic role in CPS attachment, as well as chain length, possibly involving lipid binding. 
In order to study this potential LytR function in GBS, a mutant CpsA protein was created 
containing two substitution mutations at amino acid residues R378 (polar) and Q382 
(charged). Both residues were mutated to the nonpolar amino acid alanine; if these two 
amino acids are necessary for LytR function, this change from polar and charged residues 
to nonpolar residues should lead to decreased functionality. Because LytR function is 
thought to involve regulation of chain length and CPS attachment, expression of this 
constructed mutant would produce an abnormal long chain and low CPS level phenotype 
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in WT GBS. To test these changes, the mutant CpsA was expressed in ∆cpsA and WT GBS 
variants. Chain length was quantified manually, cell envelope integrity was measured with 
a fluorescent marker, and CPS level was measured via an ELISA. Finally, the effects of 
the mutation on strain virulence was measured in zebrafish to better determine how the 
LytR domain of CpsA contributes to systemic survival in vivo. In this study we confirm in 
part a role of LytR domain ligation of CPS to the cell wall through a mechanism of binding 
the phosphate group of carrier lipids. We also confirm that neither tested residue is 
responsible for the abnormal chain lengths observed in previous studies with LytR-
truncations. Finally, the R378A/Q382A mutant CpsA resulted in only minor changes to 
virulence in zebrafish embryos, and further research is required to determine whether the 
age of fish or size of dose were limiting factors.  
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METHODS 
 
 
 
Bacterial strains and culturing 
Plasmids were constructed using TOP10 strain of Escherichia coli (Invitrogen). 
Transformed E. coli cells were grown aerobically in Luria-Bertani (LB) broth, or on LB 
plates each with 20 µg/mL chloramphenicol and 1.4% agar (Dot Scientific). Strains 515 
WT and 515 ∆cpsA of S. agalactiae were grown anaerobically in Todd-Hewitt broth (Dot 
Scientific) with 0.2% yeast extract and 3 µg/mL chloramphenicol. Cultures were grown on 
LB/Cam20 or THYB/Cam3 plates with 1.4% agar.  
 
CpsA-R378A/Q382A plasmid construction 
GBS 515 genomic DNA was used as a template with two sets of primers 
(1740/1942 and 1941/1672) to create two fragments of 1142 bp and 387 bp, respectively. 
Fragments were combined into one sequence using PCR SOEing with primers 1740 and 
1672, yielding a fragment of 1493bp. This fragment was purified using GeneJet Plasmid 
MidiPrep Kit (ThermoScientific) and cloned into pLZ12-rofA using PstI and BamHI 
restriction sites. The resultant plasmid was transformed into E. coli for amplification and 
purification and selected on LB-Cam20 (20 µg/mL) agar plates. Transformation was 
confirmed with PCR (primers 1740 and 1672), then the plasmid was isolated using Purelink 
HiPure Plasmid Filter DNA Purification Kit (Invitrogen). This was transformed into both 
515 ∆cpsA and 515 WT strains of GBS, and positive transformants were selected by growth 
on THYB-Cam3 (3 µg/mL) agar plates. Transformation into GBS strains was also 
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confirmed using PCR (using primers 1672 and 292 for WT and primers 1740 and 1672 for 
∆cpsA). The final amino acid mutant is shown in Supplementary Fig. 1.  
 
 
Figure 1. Plasmid map of the pLZ12-rofA-pro used to construct the final plasmid in this study. Vector DNA 
was stored in freezer stocks and isolated using a DNA isolation kit. The PstI and BamHI restriction sites were 
used as insertion sites for the mutant cpsA, and  chloramphenicol was used as a selectable marker for positive 
E. coli and GBS transformants. 
 
 
Figure 2. cpsA primer binding sites and mutation locations (A), and protein structural map (B). Mutation 
mapping was done using SnapGene (15), and structural mapping was adapted from UnitPro cpsA accession 
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Q9ALX6 (16).  CpsA structure includes three transmembrane domains (TM), an accessory domain, and the 
LytR domain. GBS cpsA was isolated in two fragments using PCR; one primer from each primer set 
contained the desired double mutation. A full cpsA gene with the desired mutations was created from these 
fragments using a PCR SOEing reaction, and confirmed using gel electrophoresis. The final genomic 
fragment was digested with BamHI and PstI in preparation for ligation into the digested vector.  
 
Table 1. Primers used for PCR and plasmid construction. Endonuclease cut sites are underlined.    
Primer Name Abbreviation 5’– 3’ Sequence  
5' GBS-CpsA-met 1865 ATGTCTAATCATTCGCGCCGTC 
3' CpsA-del1-PstI 1671 GCTTCATACTCTGAAATTGAGTAACTGCAGTTTT 
3' GBS CpsA-full-PstI 1672 GAACACAATGGAGGAATAACTGCAGTTTT 
3' CpsA-LytR-Del-PstI 1673 CTTTTGGCTCTATATCAACATAACTGCAGTTTT 
5' CpsA-Fwd-BglII 1837 TCAACAGTATCAAGATCTGATG 
5' CpsA R378A/Q382A/Q3 1941 TAACGATGCAGGTAGAAATGCAGAAAAAGTGATTGCAGC 
3' CpsA R378A/Q382A/Q3 1942 GCTAACGATGCAGGTAGAAATGCAGAAAAAGTGATTGCAGC 
5' GBS CpsA-RBS-BamHI 1740 GATTAGACATTGTAATTCTCCAATACGGATCCGCG 
5’GFPuv-RBS-EcoRI 292 CCGGAATTCCGGAGGAGGAAAAATATGAGTAAAGGAGAAGAAC 
 
FL-Vancomycin CpsA localization analysis 
∆cpsA and 515 strains of GBS were grown to an OD600 of 0.5 in ThyB-Cam3 broth. 
Cells were stained with BODIPY_FL vancomycin (Invitrogen) at 1µg/µL for 10 min, then 
transferred to a glass slides with coverslips. A Zeiss Axioscop fluorescence microscope 
was used for imaging.    
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Enzyme-linked immunosorbent assay (ELISA) capsule level analysis 
Strains were grown in THYB-Cam3 broth grown at 37°C overnight. These cultures 
were normalized to OD600 of 0.75, pelleted, and washed 3 times with Tris-buffered saline 
+ tween (TBST). Primary antibody (rabbit anti-Serotype 1a GBS) was diluted to 1:20,000, 
secondary antibody (secondary goat, anti-rabbit IgG conjugated to alkaline phosphatase 
(AP)) was diluted to 1:100. Secondary antibody was pre-adsorbed to prevent nonspecific 
binding using both ∆cpsA and WT GBS strains. Cells were incubated with 1µL primary 
antibody at 4˚C for 1 hr before 3 TBST washes. Cells were then incubated with secondary 
antibody for 1 hr at 4˚C before 3 TBST washes. Cells were resuspended in TBST and 
transferred to a 96-well plate. Alkaline phosphatase activity was measured after 1 hr dark 
incubation at 37°C after addition of p-nitrophenyl phosphate with alkaline phosphatase 
(Sigma). OD405 and OD600 were used to calculate activity, and each sample was done in 
triplicate.   
Zebrafish virulence assays 
Larval zebrafish infections were completed at 2 dpf using 2 nL injections into the 
yolk sac with 100 CFU inoculums of log phase bacterial cultures.  
 
Statistical significance analyses 
Numerical data was processed using a Student’s T-Test, with Bonferroni and 
Holms post hoc.  
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RESULTS 
 
 
 
In order to determine the functional amino acid residues of the LytR domain of 
CpsA, a CpsA-R378A/Q382A double mutant was created and expressed episomally in two 
GBS strains (Fig. 1, Fig. 2). Both amino acid residues are predicted to bind to the polar 
head group of the carrier lipid during CPS attachment. The effects of this mutation are 
therefore necessary to confirm this role. Previous reports demonstrated abnormal chain 
length and capsular phenotypes of the WT with cpsA truncations or deletions. Therefore, 
several methods were used to test these properties with the constructed mutant. Chain 
lengths were observed for ∆cpsA and WT strains using brightfield microscopy (Fig. 3, Fig. 
4). Both strains expressing the vector (∆cpsA-vector and WT-vector) were used as negative 
controls, and both strains expressing WT-CpsA (∆cpsA-pWT-CpsA and WT-pWT-CpsA) 
were used as positive controls.  
 
 
Figure 3. Chain length visualization with a brightfield microscope at 1000X magnification of ∆cpsA and WT 
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 carrying the empty plasmid vector, the vector plus WT-CpsA, or the vector plus CpsA-R378A/Q382A as 
labeled.  
 
 
Figure 4. CpsA-R378A/Q382A induces an increase in short chain length in WT and does not complement 
for WT chain length in ∆cpsA. Chain length was quantified manually as the number of cells in each 
streptococcal chain using 20 brightfield non-overlapping microscopy images. Histograms were used to find 
the number of chains with 1–3, 3–5, 5–7, 7–9, 9–10, and >10 cells/chain for each sample,  and frequency 
values were divided by the total number of chains to determine percentage of total chains in each length 
group.  
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Figure 5. CpsA-R378A/Q382A induced an overall increase in average chain length in the ∆cpsA strain and 
a decrease in the average chain length in the WT strain. Chain length counts were averaged and measured for 
statistically significant change (*p<0.05, **p<<<<0.05).  Error bars represent standard deviation.  
 
Full LytR-truncated CpsA in previous studies has been shown to contribute to a 
long chain phenotype when expressed in WT GBS. We first questioned whether CpsA-
R378A/Q382A would produce similar effects as this truncation, which would indicate that 
these residues are involved in this abnormal phenotype. Chain length has been shown to 
correlate to virulence, and thus any induced increase in chain length could indicate a 
decrease in virulence. Chain lengths were quantified manually from brightfield images 
(Fig. 3, Fig. 4). Both vector variants displayed a similar frequency of short chains less than 
3 cells/chain; WT-vector strain had 46% while ∆cpsA-vector had 48% (Fig. 5). Both 
	 	 	
	
	 13 
variants had different long chains greater than 10 cells/chain; WT-vector had 4% while 
∆cpsA-vector had 12%. Plasmid expression of WT-CpsA induced a slight decrease in 
frequency of longer chains in the WT, where chains of less than 3 cells/chain increased to 
51%. In contrast, plasmid expression of WT-CpsA in ∆cpsA induced a decrease in the 
frequency of chains less than 3 cells/chain to 35% of the total chains counted. The WT-
pCpsA-R378A/Q382A mutant had a much larger frequency of chains less than the WT-
vector, with 68% of chains counted being shorter than 3 cells/chain. ∆cpsA-pCpsA-
R378A/Q382A showed an overall decrease in short chain compared to ∆cpsA-vector, with 
29% of chains having less than 3 cells/chain and 18% of chains having greater than 10 
cells/chain.  
In order to find statistically significant changes chain length in these strains, chain 
length averages were taken and compared using a T-test. The averages for each strain were 
6 cells/chain (± 5 cells) and 5 cells/chain (± 2 cells), respectively. The chain length average 
for ∆cpsA-pWT-CpsA was 6 cells/chain (± 2 cells), while the WT-pWT-CpsA strain was 
4 cells/chain (± 2 cells). The average for the ∆cpsA-pCpsA-R378A/Q382A strain was 7 
cells/chain (± 3 cells), and the average for the WT-pCpsA-R378A/Q382A was 3 cells/chain 
(± 1 cells). There was a minor but significant increase in chain length in ∆cpsA-pCpsA-
R378/Q382A compared to the ∆cpsA-vector and ∆cpsA-pWT-CpsA strains (7 cells/chain, 
6 cells/chain, 6 cells/chain). Along with these changes in ∆cpsA, there was small significant 
decrease in chain length in the WT-pWT-CpsA compared to WT-vector (4 cells/chain, 5 
cells/chain), and a large significant decrease in chain length in the WT-pCpsA-
R378A/Q382A chain length (3 cells/chain). In comparing both strain variants, there was a 
significant increase in average chain length of the ∆cpsA-pCpsA-R378A/Q382A compared 
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to the WT-vector chain length (7 cells/chain, 5 cells/chain). A similar increase in average 
chain length was observed in the ∆cpsA-pWT-CpsA strain compared to WT-vector (6 
cells/chain, 5 cells/chain). The connection between CpsA and these observed changes to 
chain length is unclear, but one potential explanation could involve the process of cell 
division. Streptococcal cell division involves partial degradation of the cell envelope 
connecting two cells, and thus CpsA could be involved somehow in regulating the 
frequency of this degradation. 
 
 
 
 
Figure 6. CpsA-R378A/Q382A does not induce a change in cell envelope morphology in WT or ∆cpsA. Cells 
were normalized to the same concentration, incubated with fluorescent vancomycin to visualize cell shape 
and peptidoglycan integrity, and viewed at 1000X magnification with a widefield fluorescent microscope.  
 
Because the observed phenotypic changes in chain length could be due to a change 
in cell wall morphology, we questioned whether the cell wall shape had changed between 
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samples. Vancomycin is an antibiotic which binds to the peptidoglycan of bacterial cells, 
and therefore was used in conjugation with a fluorescent tag to more directly visualize the 
shape and integrity of the peptidoglycan layer (Fig. 6). Bacterial cells were stained with 
fluorescent vancomycin and viewed with a fluorescent microscope. No immediately 
noticeable abnormalities to cell symmetry, septal structure, nor cell viability were observed 
between samples. This indicated that the changes to chain length were likely not directly 
related to cell envelope structure.  
 
 
Figure 7. CpsA-R378A causes a dominant-negative decrease in CPS levels in WT strain and does not 
complement for CPS level in the ∆cpsA strain. An indirect ELISA was used to measure the levels of bound 
CPS for each strain variant. The secondary antibody was conjugated to alkaline phosphatase (AP), and AP 
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units therefore correlate to the level of membrane-bound CPS. Tests were done in triplicate for statistical 
analysis (**p<<0.05, ***p<<<<0.05, error bars represent standard deviation).  
 
Following this abnormal chain length morphology, another major phenotypic 
change following expression of a full LytR-truncated CpsA from previous studies was a 
change in CPS level. Therefore, we next questioned whether CpsA-R378A/Q382A would 
produce this same effect, thus indicating that these residues are necessary for production 
or attachment of CPS. To measure CPS level, an indirect ELISA was performed using a 
primary antibody that binds to CPS. A secondary antibody which is conjugated to alkaline 
phosphatase binds to this primary antibody and converts the added PNPP substrate to the 
colored PNP, thus acting as an indicator level of bound secondary antibody. The level of 
CPS therefore directly correlates to alkaline phosphatase units (Fig. 7). Only the vector and 
CpsA-R378A/Q382A strain variants were utilized for this assay. Major significant 
decreases in capsule levels were observed between WT-vector and WT-pCpsA-
R378A/Q382A (From around 8000 AP units to 6000 AP units), as well as between ∆cpsA-
vector and ∆cpsA-pCpsA-R378A/Q382A (around 4500 AP units to 4000 units). 
Additionally, ∆cpsA-vector had significantly lower capsule levels compared to WT-vector 
(8000 AP units to 4500 units), and a similar result was noticed between both respective 
LytR-mutants (6000 AP units to 4000 units). Because CPS level is a necessary virulence 
factor for GBS, these reductions in CPS level could correlate to changes to the success and 
extent of systemic infection.  
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Figure 8. CpsA-R37A/Q382A caused WT GBS to be more virulent, and ∆cpsA to be less virulent. Survival 
curves were generated using 50 zebrafish larvae per sample at with 100 CFU yolk-sac infections. Zebrafish 
larvae were infected at 2 dpf and monitored every 24 hours for 72 hours.  
 
Because increases in streptococcal chain length and reductions in CPS level have 
been associated with reductions in GBS virulence, the effects of CpsA-R378A/Q382A 
were observed in vivo with the zebrafish model. Zebrafish larvae were infected with the 
vector and mutant variants into the yolk sac and monitored for survival over 72 hours (Fig. 
8). WT-vector, ∆cpsA-vector, and ∆cpsA-pCpsA-R378A/Q382A each had near 95% 
survival by 24 hours, while WT-pCpsA-R378A/Q382A had 76%. By 48 hours, ∆cpsA-
vector had 63%, ∆cpsA-pCpsA-R378A/Q382Aa had 57%, WT-vector had 46%, and WT-
pCpsA-R378A/Q382A had 36%. By 72 hours, both ∆cpsA-pCpsA-R378A/Q382A and 
WT-vector had near 30%, while ∆cpsA-vector had 15% and WT-pCpsA-R378A/Q382A 
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had 7%. Overall, WT-pCpsA-R378A/Q382A showed the highest increase in virulence 
compared to the vector variant, while ∆cpsA-pCpsA-R378A/Q382A showed the highest 
reduction in virulence compared to the vector variant.  
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DISCUSSION 
	
	
GBS CpsA is a multifunctional regulator of cell envelope composition. 
While GBS produces a variety of virulence factors, capsule is specifically crucial 
as it allows for survival in the host bloodstream by preventing destruction by immune 
factors. Capsule operon expression, CPS attachment, and cell wall maintenance are 
accomplished through interactions with the CpsA protein. The exact functional mechanism 
used by the  CpsA protein is not well understood, but comparisons to homologous proteins 
have led to several intriguing predictions about particular domain function. 
The LytR domain of GBS CpsA has homology to LytR proteins of other 
streptococcal bacteria such as S. pneumoniae. LytR proteins regulate capsule attachment 
and contribute to forming the septum, thus controlling cell size and chain length (12). When 
S. pneumoniae Cps2A is missing or nonfunctional, the LytR protein can complement for 
normal capsule production in place of CpsA (12). A strain of S. pneumoniae that 
suppressed both CpsA and LytR has a very abnormal phenotype which grows poorly and 
releases large amounts of CPS, indicating lack of capsule attachment (12). Crystal structure 
analysis of Cps2A also suggests a mechanism for this phenotypic change, in that the LytR 
domain of Cps2A binds lipids, consistent with a role in attachment of CPS to the cell wall 
(13). 
Based on these data from studies on S. pneumoniae, the LytR domain of GBS CpsA 
was predicted to be associated with CPS attachment to peptidoglycan. In a previous study 
from our lab, mutations to the amino acids in the putative metal binding region of GBS 
CpsA expressed from a plasmid, prevented capsule production complementation in 
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the  ∆cpsA strain, suggesting that the LytR domain uses metal ions to perform any 
respective functions (14). While this contributes to a confirmation for an enzymatic 
function of the LytR domain, little experimental evidence has been procured to confirm the 
exact role this function plays on chain length and capsule levels in GBS. 
In order to address this gap in knowledge, a double mutant of CpsA was created 
with two polar to non-polar amino acid mutations in the LytR domain. The mutated amino 
acids residues, R378 and Q382, were predicted to bind to the phosphate head group of 
lipids based on Cps2A crystal structure data. 
  
CpsA-R378A/Q382A causes reductions in long chain frequency in WT GBS. 
To begin analysis of mutant CpsA, several strains of GBS with and without the 
constructed mutant were analyzed for chain length. The frequency variation for the deletion 
strain is lower than reported in previous studies, but ∆cpsA still had a higher proportion of 
chains greater than 10 cells/chain compared to WT. This is consistent with previous 
findings and suggest that deletion of CpsA contributes to increased chain length. The 
observed chain length trends indicate that the WT-CpsA does not complement for short 
WT chain length in ∆cpsA, but in fact increases it. Similarly, the CpsA-R378A/Q382A 
mutant induced an even greater reduction in short <3 cell chains, indicating that the mutant 
complements less than the WT-CpsA. Conversely, chain length frequency trends for the 
WT strain indicate that the LytR-mutant contributes to short chains being even more 
frequent.  
Chain length averages for ∆cpsA had large variability, however, and therefore are 
unlikely to be meaningful despite slight statistical significance between the mutant and 
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pWT-CpsA variants. Conversely, WT-vector, WT-pWT-CpsA, and WT-pCpsA-
R378A/Q382A show a significant downward trend in chain lengths, with the mutant having 
shorter average chain length than the WT-vector strain. Percentage graphs for the 
frequency of chain lengths additionally confirm this result, as chains with less than 3 cocci 
were much more frequent in the WT-pCpsA-R378A/Q382A strain compared to the WT-
vector strain. Previous studies have indicated that expression of LytR-truncated CpsA in 
WT GBS causes a drastic change in chain length, with a majority of chains being longer 
than 10 cells (7). Because this long chain phenotype was not observed in the WT-pCpsA-
R378A/Q382A variant, we can conclude that residues R378 and Q382 are not responsible 
for the long chain phenotype. Chain length quantification studies on additional LytR 
mutants would be necessary to determine the actual causative region of this phenotype. 
Such data would also provide a more expansive reference on the connection to chain length 
and CPS production; such connections cannot be made from the data herein. These data do 
suggest, however, that LytR-mutated CpsA causes WT chains become shorter. This could 
mean that the constructed mutation is gain-of-function for CpsA, or potentially that 
functional LytR domain interacts with cell wall degradation factors during cell division 
and thus non-functional LytR leads to aberrant regulation of chain length. 
 
Cell wall FL-Vancomycin shows no visible changes in cell wall morphology. 
Following chain length results, cell wall integrity was checked to determine if the 
mutant CpsA causes morphological abnormalities. No difference was noticed between any 
strain in terms of cell wall morphology after incubation with FL-vancomycin. Disruptions 
to cell wall morphology could indicate abnormal cell division or abnormal cell wall 
maintenance, which could be connected to predicted cell wall enzymes like LytR of CpsA. 
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However, because no abnormalities were observable here under brightfield microscopy, 
we cannot conclude that the CpsA-R378A/Q382A mutant affects cell wall maintenance. 
We can surmise, however, that residues R378 and Q382 are likely not major contributors 
to regulation of cell division or cell shape, as no aberrant septum formation or cell shape 
was noted.  
  
CpsA-R378A/Q382A causes decreased CPS level in both ∆cpsA and WT GBS. 
ELISA data confirmed previous findings that WT GBS has much higher CPS levels 
than the ∆cpsA strain, with a statistically significant difference of around 3600 AP units 
between the two strains. Interestingly, expression of CpsA-R378A/Q382A in both WT and 
∆cpsA strains caused a significant decrease in CPS production from each respective control 
strain, thus indicating that the substitution mutations to the LytR domain do indeed cause 
a decrease in CPS production, or alternatively in CPS attachment, as any unbound-CPS 
was washed off of the cells before the assay. Quantification of CPS levels unbound to cells 
(i.e. supernatant from washes) would be necessary to determine which conclusion is more 
likely. Higher levels of CPS in the supernatant of the ∆cpsA-pCpsA-R378A/Q382A strains 
would likewise indicate that the observed decrease in bound capsule is in fact due to lack 
of attachment, rather than lack of CPS production or expression. Additionally, the decrease 
in CPS levels likely involves a repressive effect on WT CpsA because the downregulation 
of CPS levels was observed in a GBS strain which produces endogenous and fully-
functional CpsA. Previous studies have suggested that the LytR domain acts as a ligase, 
transferring CPS from a carrier lipid to peptidoglycan via phosphate transfer reactions (13, 
Supplementary Fig. 2). Overall, we propose that the substitution mutation to the LytR 
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domain yields a non-functional or mis-functional protein which cannot attach CPS to the 
peptidoglycan as well as WT CpsA, and additionally impedes WT-CpsA function through 
some repressive, dominant negative effect.  
 
CpsA-R378A/Q382A has a minor effect on virulence in zebrafish. 
The zebrafish model is a proven model for neonatal systemic GBS infection (12). 
Larval zebrafish are especially useful as they have not yet developed an adaptive immune 
system and display an acute infection response that is easy to identify. On top of this, 
zebrafish embryos are transparent, meaning that live infection responses can be monitored 
visually through labeled innate immune factors. Research on CpsA has revealed that ∆cpsA 
caused significantly lower mortality in zebrafish than the WT model (12). Studies on 
bacterial burden in major zebrafish organs showed additionally that ∆cpsA has less 
dissemination in zebrafish than WT, and that CpsA truncated before the LytR domain had 
even further reductions in dissemination (11). Further, human whole blood analysis 
indicated that GBS with LytR-truncated CpsA had much lower survival than WT and 
∆cpsA strains (12). 
Previous studies noted major significant decrease in mortality between the ∆cpsA 
and WT variants of GBS (11,12). The results herein are not fully consistent with these 
findings, as WT-vector was only more virulent than ∆cpsA-vector at 48 hpi; ∆cpsA-vector 
was in fact more virulent than WT-vector at 72 hrs. WT-pCpsA-R378A/Q382A was the 
most virulent strain, with a consistent 10–20% mortality at each timepoint. These 
differences are minimal compared to the 60% difference observed in adult zebrafish in 
Rowe et al (11). It’s possible that the LytR-mutant created a more virulent WT GBS strain, 
but it is more likely that these results were due to the experimental design. Because 
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previous studies reported GBS infection in adult zebrafish, it’s possible that zebrafish 
embryos are not ideal for use of altered strains. The WT GBS variant is highly virulent 
likely as a result of excellent control of CPS levels, resulting in decreased levels for 
macrophage infection and transport to target tissues, as well as increased levels inside 
macrophages or during colonization to prevent immune cell-mediated degradation. The 
∆cpsA strain as well as the R378A/Q382A variants, however, have large reductions in such 
CPS. Perhaps, recognition by immune cells is enhanced as a result to a higher degree than 
each phagocyte can handle, thus resulting in the infection spreading regardless throughout 
the bloodstream into every tissue. Further experiments would be necessary using lower 
doses to determine if the embryo model can be utilized for such experiments in the future. 
Alternatives could additionally include intramuscular injection of adult zebrafish which 
might be better suited to longer term survival monitoring.  
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CONCLUSIONS 
 
 
 
These findings as a whole are consistent with the function of the LytR domain of 
CpsA as a catalyst for CPS attachment to the peptidoglycan. CPS attachment to 
peptidoglycan in streptococci is thought to involve polysaccharide synthesis, linkage of the 
CPS to lipid carriers, and transfer of CPS from the inside of the cell to the outside using 
phosphate transfer reactions (13, Supplementary Fig. 2). This transfer would involve CpsA 
acting as an enzyme catalyst, and this process has been experimentally confirmed to require 
a metal ion like Mg2+ (10, 16). The decreases in CPS levels induced by R378A/Q382A 
expression observed herein are consistent with such a mechanism, in that less CPS is 
ligated to the peptidoglycan because the residues responsible for carrier lipid binding no 
longer have the necessary negative charge. In addition to this finding, the CpsA-
R378A/Q382A mutant did not cause an increased chain length phenotype when expressed 
in WT GBS, likely indicating that neither of these amino acid residues is responsible for 
the abnormal chain length phenotype observed in previous research. CpsA-R378A/Q382A 
caused WT GBS to be more virulent than the WT-vector strain, but additionally caused an 
decrease in virulence in ∆cpsA.  Further experiments are necessary to fully confirm these 
results, as well as to determine their application to human therapeutics. 
 
 
	
	
 
	
	
	 	 	
	
	 26 
 
VI. FUTURE DIRECTIONS 
	
	
This study confirmed in part the importance of residues R378 and Q382 of CpsA 
in production of CPS in GBS. Targeting of regions such as these could be very valuable, 
as CpsA-target vaccines for GBS would be non-serotype specific. These findings are not 
sufficient on their own to explain the full mechanism of CpsA function, as many amino 
acids are predicted to be involved in lipid binding. As such, each of these additional 
residues should also be analyzed for contributions to phenotypic changes in order to 
determine the full spectrum of activity of this protein. Analysis of supernatant from each 
mutant strain is also necessary to definitively confirm that the LytR domain mutations are 
responsible for decreased attachment, rather than decreased capsule operon transcription 
and CPS production. Finally, further zebrafish model analysis is necessary to better 
elucidate the effects of these CpsA mutations on virulence, and whether the dosage or age 
of the fish had an effect on the observed results. 
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Supplementary Figure 1. WT CpsA (query) versus CpsA-R375A/Q382A (sbjct). The mutated region is 
indicated by upwards and downwards brackets. Alignment created using BlastP (18).  
 
 
 
Supplementary Figure 2. Membrane topology and predicted function of CpsA. The LytR domain is predicted 
to bind carrier lipids for CPS and transfer the CPS to the peptidoglycan. 
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